Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group

• Published in: Investigational new drugs Vol. 41; no. 2; pp. 340 - 349
• Main Authors: Takaki, Shintaro, Kurosaki, Masayuki, Mori, Nami, Tsuji, Keiji, Ochi, Hironori, Marusawa, Hiroyuki, Nakamura, Shinichiro, Tada, Toshifumi, Narita, Ryoichi, Uchida, Yasushi, Akahane, Takehiro, Kondo, Masahiko, Kusakabe, Atsunori, Furuta, Koichiro, Kobashi, Haruhiko, Arai, Hirotaka, Nonogi, Michiko, Tamada, Takashi, Hasebe, Chitomi, Ogawa, Chikara, Sato, Takashi, Tamaki, Nobuharu, Yasui, Yutaka, Tsuchiya, Kaoru, Izumi, Namiki
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.04.2023; Springer Nature B.V
• Subjects: Adverse events; Alanine; Alanine transaminase; Aspartate aminotransferase; Bevacizumab; Bevacizumab - adverse effects; Bilirubin; Carcinoma, Hepatocellular - drug therapy; Hepatocellular carcinoma; Humans; Immunotherapy; Japan; Liver cancer; Liver Neoplasms - drug therapy; Medicine; Medicine & Public Health; Multivariate analysis; Oncology; Pharmacology/Toxicology; Proteinuria; Red Cross; Retrospective Studies; Risk factors; Survival; Transaminases; Japan; Unresectable HCC; Proteinuria; Atezolizumab; Bevacizumab
• ISSN: 0167-6997; 1573-0646
• DOI: 10.1007/s10637-023-01349-4

Summary This study aimed to describe the real-world efficacy and safety of the combination therapy of atezolizumab and bevacizumab (Atezo/Bev) for unresectable hepatocellular carcinoma (HCC). This retrospective analysis of a multicenter registry cohort included 268 patients treated with Atezo/Bev. The incidence of adverse events (AE) and its impact on overall survival (OS) and progression-free survival (PFS) were analyzed. Of the 268 patients, 230 (85.8%) experienced AE. The median OS and PFS in the whole cohort were 462 and 239 days, respectively. The OS and PFS were not different in terms of AE, but they were significantly shorter in patients with increased bilirubin level and those with increased aspartate aminotransferase (AST) or alanine aminotransferase (ALT). Regarding increased bilirubin level, the hazard ratios (HRs) were 2.61 (95% confidence interval [CI]: 1.04–6.58, P = 0.042) and 2.85 (95% CI: 1.37–5.93, P = 0.005) for OS and PFS, respectively. Regarding increased AST or ALT, the HRs were 6.68 (95% CI: 3.22–13.84, P < 0.001) and 3.54 (95% CI: 1.83–6.86, P < 0.001) for OS and PFS, respectively. Contrarily, the OS was significantly longer in patients with proteinuria (HR: 0.46 [95% CI: 0.23–0.92], P = 0.027). Multivariate analysis confirmed that proteinuria (HR: 0.53 [95% CI: 0.25–0.98], P = 0.044) and increased AST or ALT (HR: 6.679 [95% CI: 3.223–13.84], P = 0.003) were independent risk factors for a shorter OS. Furthermore, analysis limited to cases who completed at least 4 cycles confirmed that increased AST or ALT and proteinuria were negative and positive factors for OS, respectively. In the real-world setting, increased AST or ALT and bilirubin level during Atezo/Bev treatment were found to have a negative impact on PFS and OS, whereas proteinuria had a positive impact on OS.